In December 2009, the new President of the European Commission (EC), José Manuel Barroso, announced that the management of pharmaceutical policy will be transferred from the EC’s Enterprise and Industry directorate to its Health and Consumer Policy directorate (known as DG SANCO), a long-awaited switch. The approach taken by the Enterprise and Industry directorate appears to …